PAHC Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 2.68% compared to Phibro Animal Health's net margin of 8.28%. Phibro Animal Health's return on equity of 6.55% beat Globus Medical's return on equity of 2.27%.

Phibro Animal Health has a consensus price target of $19.40, signalling downside risk potential of -5.46%. On the other hand Globus Medical has an analysts' consensus of $93.85 which suggests that it could grow by 13.82%. Given that Globus Medical has higher upside potential than Phibro Animal Health, analysts believe Globus Medical is more attractive than Phibro Animal Health.

Phibro Animal Health has a beta of 0.527, which suggesting that the stock is 47.336% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Phibro Animal Health has a quarterly dividend of $0.12 per share corresponding to a yield of 2.34%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health pays 804.72% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Phibro Animal Health quarterly revenues are $260.4M, which are smaller than Globus Medical quarterly revenues of $625.7M. Phibro Animal Health's net income of $7M is lower than Globus Medical's net income of $51.8M. Notably, Phibro Animal Health's price-to-earnings ratio is 47.72x while Globus Medical's PE ratio is 123.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health is 0.79x versus 4.58x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 2.68% compared to Phibro Animal Health's net margin of 9.79%. Phibro Animal Health's return on equity of 6.55% beat Haemonetics's return on equity of 13.51%.

Phibro Animal Health has a consensus price target of $19.40, signalling downside risk potential of -5.46%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 38.41%. Given that Haemonetics has higher upside potential than Phibro Animal Health, analysts believe Haemonetics is more attractive than Phibro Animal Health.

Phibro Animal Health has a beta of 0.527, which suggesting that the stock is 47.336% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

Phibro Animal Health has a quarterly dividend of $0.12 per share corresponding to a yield of 2.34%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health pays 804.72% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Phibro Animal Health quarterly revenues are $260.4M, which are smaller than Haemonetics quarterly revenues of $345.5M. Phibro Animal Health's net income of $7M is lower than Haemonetics's net income of $33.8M. Notably, Phibro Animal Health's price-to-earnings ratio is 47.72x while Haemonetics's PE ratio is 33.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health is 0.79x versus 3.02x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 2.68% compared to Phibro Animal Health's net margin of 14.25%. Phibro Animal Health's return on equity of 6.55% beat Insulet's return on equity of 49.55%.

Phibro Animal Health has a consensus price target of $19.40, signalling downside risk potential of -5.46%. On the other hand Insulet has an analysts' consensus of $289.72 which suggests that it could grow by 8.79%. Given that Insulet has higher upside potential than Phibro Animal Health, analysts believe Insulet is more attractive than Phibro Animal Health.

Phibro Animal Health has a beta of 0.527, which suggesting that the stock is 47.336% less volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

Phibro Animal Health has a quarterly dividend of $0.12 per share corresponding to a yield of 2.34%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health pays 804.72% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Phibro Animal Health quarterly revenues are $260.4M, which are smaller than Insulet quarterly revenues of $543.9M. Phibro Animal Health's net income of $7M is lower than Insulet's net income of $77.5M. Notably, Phibro Animal Health's price-to-earnings ratio is 47.72x while Insulet's PE ratio is 45.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health is 0.79x versus 10.26x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 2.68% compared to Phibro Animal Health's net margin of 25.43%. Phibro Animal Health's return on equity of 6.55% beat ResMed's return on equity of 23.76%.

Phibro Animal Health has a consensus price target of $19.40, signalling downside risk potential of -5.46%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 10.65%. Given that ResMed has higher upside potential than Phibro Animal Health, analysts believe ResMed is more attractive than Phibro Animal Health.

Phibro Animal Health has a beta of 0.527, which suggesting that the stock is 47.336% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Phibro Animal Health has a quarterly dividend of $0.12 per share corresponding to a yield of 2.34%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Phibro Animal Health pays 804.72% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Phibro Animal Health's is not.

Phibro Animal Health quarterly revenues are $260.4M, which are smaller than ResMed quarterly revenues of $1.2B. Phibro Animal Health's net income of $7M is lower than ResMed's net income of $311.4M. Notably, Phibro Animal Health's price-to-earnings ratio is 47.72x while ResMed's PE ratio is 30.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health is 0.79x versus 7.11x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.